440 related articles for article (PubMed ID: 24035998)
1. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.
Huang KT; Pavlides SC; Lecanda J; Blank SV; Mittal KR; Gold LI
PLoS One; 2012; 7(9):e46072. PubMed ID: 23029392
[TBL] [Abstract][Full Text] [Related]
3. TGF-β activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth.
Pavlides SC; Lecanda J; Daubriac J; Pandya UM; Gama P; Blank S; Mittal K; Shukla P; Gold LI
Cell Cycle; 2016; 15(7):931-47. PubMed ID: 26963853
[TBL] [Abstract][Full Text] [Related]
4. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase.
Bashir T; Dorrello NV; Amador V; Guardavaccaro D; Pagano M
Nature; 2004 Mar; 428(6979):190-3. PubMed ID: 15014502
[TBL] [Abstract][Full Text] [Related]
5. CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation.
Appleman LJ; Chernova I; Li L; Boussiotis VA
Cell Cycle; 2006 Sep; 5(18):2123-9. PubMed ID: 16969077
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.
Ungermannova D; Lee J; Zhang G; Dallmann HG; McHenry CS; Liu X
J Biomol Screen; 2013 Sep; 18(8):910-20. PubMed ID: 23589337
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.
Hao B; Zheng N; Schulman BA; Wu G; Miller JJ; Pagano M; Pavletich NP
Mol Cell; 2005 Oct; 20(1):9-19. PubMed ID: 16209941
[TBL] [Abstract][Full Text] [Related]
8. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
[TBL] [Abstract][Full Text] [Related]
9. Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
Uehara N; Yoshizawa K; Tsubura A
Oncol Rep; 2012 Jul; 28(1):105-10. PubMed ID: 22484732
[TBL] [Abstract][Full Text] [Related]
10. Cryo-EM structure of SKP1-SKP2-CKS1 in complex with CDK2-cyclin A-p27KIP1.
Rowland RJ; Heath R; Maskell D; Thompson RF; Ranson NA; Blaza JN; Endicott JA; Noble MEM; Salamina M
Sci Rep; 2023 Jul; 13(1):10718. PubMed ID: 37400515
[TBL] [Abstract][Full Text] [Related]
11. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.
Gupta P; Zhao H; Hoang B; Schwartz EL
Br J Cancer; 2022 Oct; 127(6):969-975. PubMed ID: 35752713
[TBL] [Abstract][Full Text] [Related]
12. Cks1 promotion of S phase entry and proliferation is independent of p27Kip1 suppression.
Hoellein A; Graf S; Bassermann F; Schoeffmann S; Platz U; Hölzlwimmer G; Kröger M; Peschel C; Oostendorp R; Quintanilla-Fend L; Keller U
Mol Cell Biol; 2012 Jul; 32(13):2416-27. PubMed ID: 22508990
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor upregulates Skp2/Cks1 and p27(kip1) in human extrahepatic cholangiocarcinoma cells.
Kim JY; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim DH; Chae SW; Sohn JH
World J Gastroenterol; 2014 Jan; 20(3):755-73. PubMed ID: 24574749
[TBL] [Abstract][Full Text] [Related]
14. Substrate recognition and ubiquitination of SCFSkp2/Cks1 ubiquitin-protein isopeptide ligase.
Xu S; Abbasian M; Patel P; Jensen-Pergakes K; Lombardo CR; Cathers BE; Xie W; Mercurio F; Pagano M; Giegel D; Cox S
J Biol Chem; 2007 May; 282(21):15462-70. PubMed ID: 17409098
[TBL] [Abstract][Full Text] [Related]
15. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Old JB; Kratzat S; Hoellein A; Graf S; Nilsson JA; Nilsson L; Nakayama KI; Peschel C; Cleveland JL; Keller UB
Mol Cancer Res; 2010 Mar; 8(3):353-62. PubMed ID: 20197382
[TBL] [Abstract][Full Text] [Related]
16. Skp2-mediated p27(Kip1) degradation during S/G2 phase progression of adipocyte hyperplasia.
Auld CA; Fernandes KM; Morrison RF
J Cell Physiol; 2007 Apr; 211(1):101-11. PubMed ID: 17096381
[TBL] [Abstract][Full Text] [Related]
17. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
[TBL] [Abstract][Full Text] [Related]
18. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
19. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
20. Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation.
Salamina M; Montefiore BC; Liu M; Wood DJ; Heath R; Ault JR; Wang LZ; Korolchuk S; Baslé A; Pastok MW; Reeks J; Tatum NJ; Sobott F; Arold ST; Pagano M; Noble MEM; Endicott JA
J Mol Biol; 2021 Mar; 433(5):166795. PubMed ID: 33422522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
